Publications by authors named "Clare L Murphy"
Effect of Empagliflozin on Kidney Biochemical and Imaging Outcomes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF).
Circulation
July 2022
Article Synopsis
- The study investigates how common coronary artery disease (CAD) and coronary microvascular dysfunction (CMD) are in hospitalized patients suffering from heart failure with preserved ejection fraction (HFpEF).
- A total of 106 HFpEF patients were examined over a period of nearly two years, undergoing various imaging and assessment techniques to accurately evaluate their heart conditions.
- Results revealed that over half (51%) of the patients had obstructive epicardial CAD, with many showing no prior history of the disease, while two-thirds (66%) had indications of CMD.
Article Synopsis
- The study looked at patients who had heart surgery (CABG) and whether they joined a trial testing two treatment options for heart problems.
- Out of 217 patients, most either didn't want to join or weren't eligible, with 60 actually participating in the trial and 73 in a registry.
- In the end, both groups had similar long-term health results, but those in the registry had worse initial health issues compared to those in the trial.
Aims: The coronavirus disease 2019 (COVID-19) pandemic has created significant challenges to healthcare globally, necessitating rapid restructuring of service provision. This questionnaire survey was conducted amongst adult heart failure (HF) patients in the United Kingdom (UK), to understand the impact of COVID-19 upon HF services.
Methods And Results: The survey was conducted by the Pumping Marvellous Foundation, a UK HF patient charity.
Background: Microvascular dysfunction plays an important role in the pathogenesis of heart failure with preserved ejection fraction (HFpEF). However, no mechanistic link between systemic microvasculature and congestion, a central feature of the syndrome, has yet been investigated.
Objectives: This study aimed to investigate capillary-interstitium fluid exchange in HFpEF, including lymphatic drainage and the potential osmotic forces exerted by any hypertonic tissue Na excess.
Background: Sodium-glucose cotransporter 2 inhibitors reduce the risk of heart failure hospitalization and cardiovascular death in patients with heart failure and reduced ejection fraction (HFrEF). However, their effects on cardiac structure and function in HFrEF are uncertain.
Methods: We designed a multicenter, randomized, double-blind, placebo-controlled trial (the SUGAR-DM-HF trial [Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects in Patients With Diabetes Mellitus, or Prediabetes, and Heart Failure]) to investigate the cardiac effects of empagliflozin in patients in New York Heart Association functional class II to IV with a left ventricular (LV) ejection fraction ≤40% and type 2 diabetes or prediabetes.
Background: The benefits of routine invasive management in patients with prior coronary artery bypass grafts presenting with non-ST elevation acute coronary syndromes are uncertain because these patients were excluded from pivotal trials.
Methods: In a multicenter trial, non-ST elevation acute coronary syndromes patients with prior coronary artery bypass graft were prospectively screened in 4 acute hospitals. Medically stabilized patients were randomized to invasive management (invasive group) or noninvasive management (medical group).
Approaches to the treatment of anaemia in patients with chronic heart failure.
Heart Fail Rev
December 2008
An association between anaemia, poor functional status and, compared to non-anaemic patients, worse clinical status and a higher risk of hospitalisation and death has been consistently reported in chronic heart failure (CHF), although cause an effect has not been proven. While it is attractive to think that correction of a co-morbidity that exacerbates already diminished delivery of oxygen to the tissues in heart failure is likely to beneficial, the possible haemodynamic effects of increasing haemoglobin, for example vasoconstriction, might not be. Consequently, the balance of benefit and risk of anaemia correction in CHF is uncertain, may vary according to the severity of anaemia (and other factors) and needs to be properly evaluated.
View Article and Find Full Text PDF